Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Yanagisawa

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Acta Crystallographica. Section B, Structural Science|October 1, 1989
Structural study of histamine H2-receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolylmethylthio]propionamidine and -amide derivativesT Ishida, Y In, M Doi, et al.
Japanese Journal of Pharmacology|June 30, 2001
Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overloadT Tokioka-Akagi, A Fujimori, M Shibasaki, et al.
Molecular Pharmacology|April 1, 1987
On the structure-activity relationship of histamine H2-receptor antagonists based on the X-ray crystal structures and 1H-NMR spectra of amidine derivativesT Ishida, Y In, M Shibata, et al.
The Journal of Oral Implantology|January 1, 1989
Effects of "wettability" of biomaterials on culture cellsI Yanagisawa, H Sakuma, M Shimura, et al.
Chemical & Pharmaceutical Bulletin|March 22, 2000
Novel potassium channel activators. III. Synthesis and pharmacological evaluation of 3,4-dihydro-2H-1,4-benzoxazine derivatives: modification at the 2 positionY Matsumoto, A Uchida, H Nakahara, et al.
Chemical & Pharmaceutical Bulletin|December 13, 1997
Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivativesA Matsuhisa, A Tanaka, K Kikuchi, et al.
European Journal of Pharmacology|December 27, 1994
Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitorM Shibasaki, K Shibasaki, M Ichihara, et al.
Chemical & Pharmaceutical Bulletin|May 1, 1996
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivativesM Ohta, T Suzuki, T Koide, et al.
Chemical & Pharmaceutical Bulletin|September 1, 1996
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivativesM Ohta, T Suzuki, T Furuya, et al.
Bioorganic & Medicinal Chemistry|March 18, 2000
Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepineY Matsumoto, R Tsuzuki, A Matsuhisa, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Acta Crystallographica. Section B, Structural Science|October 1, 1989
Structural study of histamine H2-receptor antagonists. Five 3-[2-(diamino-methyleneamino)-4-thiazolylmethylthio]propionamidine and -amide derivativesT Ishida, Y In, M Doi, et al.
Japanese Journal of Pharmacology|June 30, 2001
Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overloadT Tokioka-Akagi, A Fujimori, M Shibasaki, et al.
Molecular Pharmacology|April 1, 1987
On the structure-activity relationship of histamine H2-receptor antagonists based on the X-ray crystal structures and 1H-NMR spectra of amidine derivativesT Ishida, Y In, M Shibata, et al.
The Journal of Oral Implantology|January 1, 1989
Effects of "wettability" of biomaterials on culture cellsI Yanagisawa, H Sakuma, M Shimura, et al.
Chemical & Pharmaceutical Bulletin|March 22, 2000
Novel potassium channel activators. III. Synthesis and pharmacological evaluation of 3,4-dihydro-2H-1,4-benzoxazine derivatives: modification at the 2 positionY Matsumoto, A Uchida, H Nakahara, et al.
Chemical & Pharmaceutical Bulletin|December 13, 1997
Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivativesA Matsuhisa, A Tanaka, K Kikuchi, et al.
European Journal of Pharmacology|December 27, 1994
Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitorM Shibasaki, K Shibasaki, M Ichihara, et al.
Chemical & Pharmaceutical Bulletin|May 1, 1996
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivativesM Ohta, T Suzuki, T Koide, et al.
Chemical & Pharmaceutical Bulletin|September 1, 1996
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivativesM Ohta, T Suzuki, T Furuya, et al.
Bioorganic & Medicinal Chemistry|March 18, 2000
Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepineY Matsumoto, R Tsuzuki, A Matsuhisa, et al.
Pageof 5